| 3.63 -0.08 (-2.16%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.95 |
1-year : | 5.78 |
| Resists | First : | 4.23 |
Second : | 4.95 |
| Pivot price | 3.4  |
|||
| Supports | First : | 3.34 |
Second : | 2.78 |
| MAs | MA(5) : | 3.69 |
MA(20) : | 3.47 |
| MA(100) : | 4.37 |
MA(250) : | 4.3 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 60 |
D(3) : | 62.3 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 6.8 | Low : | 2.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CCM ] has closed below upper band by 31.0%. Bollinger Bands are 10.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.97 - 4 | 4 - 4.02 |
| Low: | 3.53 - 3.56 | 3.56 - 3.58 |
| Close: | 3.59 - 3.64 | 3.64 - 3.67 |
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Wed, 14 Oct 2026
Concord Medical Services Holdings Limited: Performance & Quotes, CCM Stock Price on CBOE Exchange - www.marketscreener.com
Sat, 01 Aug 2026
CCM Q2 2016 Earnings: Severe EPS Disappointment Sends Shares Down 4.84% - Earnings Preview - dars.gov.et
Fri, 08 May 2026
Concord Healthcare Unveils China’s First Proton Therapy-Focused Large Language Model - BioPharma APAC
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 25.6 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -2.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -72.25 |
| Profit Margin | -20.2 % |
| Operating Margin | -36.5 % |
| Return on Assets (ttm) | -2.3 % |
| Return on Equity (ttm) | -21.9 % |
| Qtrly Rev. Growth | 57.4 % |
| Gross Profit (p.s.) | 9.15 |
| Sales Per Share | 163.3 |
| EBITDA (p.s.) | -35.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -202 (M) |
| Levered Free Cash Flow | -314 (M) |
| PE Ratio | -1.23 |
| PEG Ratio | 0.5 |
| Price to Book value | -0.06 |
| Price to Sales | 0.02 |
| Price to Cash Flow | -0.06 |
| Dividend | 9.89 |
| Forward Dividend | 0 |
| Dividend Yield | 272.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|